Gary Craig
Spokane, WANPI 1508936436
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $205,787 of the $328,202 with a category attached, or 62.7%. It is spread thinly across 22 manufacturers, the largest accounting for just 19.2%. Reporting peaked in 2019 at $203,302 and has fallen 97.1% since, to $5,841 in 2025.
Across 559 payments — averaging $587.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$63K
- Lilly USA, LLC$58K
- Regeneron Healthcare Solutions, Inc.$34K
- Novartis$29K
- UCB, Inc.$29K
- Bristol Myers Squibb$28K
- plus $87K from 16 others
Across 35 payments — averaging $2043.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$50K
- E.r. Squibb & Sons, L.L.C.$16K
- Amgen$4K
- F. Hoffmann-la Roche AG$1K
- GSK$934
What the payments were for
- Consulting fees$66,14120%
- Speaking & faculty fees$205,78763%
- Travel & lodging$44,23513%
- Food & beverage$12,0294%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 131 | $62,922 |
| Lilly USA, LLC | 99 | $58,015 |
| Regeneron Healthcare Solutions, Inc. | 41 | $34,033 |
| Novartis | 48 | $29,061 |
| UCB, Inc. | 42 | $28,883 |
| Bristol Myers Squibb | 34 | $27,986 |
| E.r. Squibb & Sons, L.L.C. | 31 | $25,233 |
| Pfizer | 32 | $24,763 |
| Gilead | 17 | $12,230 |
| Genentech USA, Inc. | 42 | $9,793 |
| F. Hoffmann-la Roche AG | 7 | $8,481 |
| Sanofi | 3 | $3,131 |
| Boehringer Ingelheim | 4 | $1,718 |
| Johnson & Johnson | 1 | $750 |
| AbbVie | 10 | $597 |
| GSK | 10 | $264 |
| AstraZeneca | 1 | $123 |
| Janssen Scientific Affairs, LLC | 1 | $69 |
| Sanofi-aventis U.S. LLC | 1 | $61 |
| Regeneron | 1 | $43 |
| Sobi, Inc | 2 | $31 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.